TrialPath

79 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

71 studies on the map

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease — Banner Alzheimer's Institute, PhoenixStudy to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease — Local Institution - 0046, HomewoodPragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults — University of Alabama at Birmingham, BirminghamA Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease — Banner Alzheimers Institute, PhoenixA Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) — Irvine Clinical Research ( Site 1041), IrvinePhase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis — ATP Clinical Research Inc., IrvineA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis — Clinical Site, PhoenixClinical Trial on Agitation in Alzheimer's Dementia — ClinCloud, LLC, MaitlandA Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) — Barrow Neurological Institute, PhoenixSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Esperanza Clinical, MurrietaA Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia — Advanced Research Center, Inc, AnaheimOpen-label Extension Study in Participants With Early Alzheimer's Disease — GSK Investigational Site, MaitlandA Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease — Irvine Center for Clinical Research /ID# 277752, IrvineClinical Study of SNK01 in Participants With Moderate Alzheimer's Disease — Behavioral Research Specialists, LLC, GlendaleA Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) — The Ohio State University (OSU) Wexner Medical Center, ColumbusSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoFerritin and Iron Burden in SAH sIRB — Univesity of Iowa Hospital and Clinics, Iowa CitySex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease — Mayo Clinic, JacksonvilleTesting the Pain Clinical Practice Guideline — Future Care Coldspring, BaltimoreAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — Clinical Site, DoralAβ Dynamics in LLMD — NYU Langone Health, New YorkSenicapoc in Alzheimer's Disease — University of California, Davis Alzheimer's Disease Center, SacramentoComparing Antipsychotic Medications in LBD Over Time — University Health System, San AntonioPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease — Johns Hopkins Center for Psychedelic and Consciousness Research, BaltimoreA Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) — Tekton Research Saint Louis Psychiatry, St LouisTrial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X) — Johns Hopkins School of Medicine, BaltimoreSafety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease — Weill Cornell Medicine Brain Health Imaging Institute, New YorkElucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia — Virginia Commonwealth University, RichmondNighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease — The University of Texas at Austin, AustinTranscranial Magnetic Stimulation Treatment for Alzheimer's Disease — Massachusetts General Hospital, BostonHuman Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. — University of Miami Department of Neurology, MiamiCholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition — Vanderbilt University Medical Center Clinical Research Center, NashvilleLongitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease — Columbia University Irving Medical Center, New YorkA Study of AMDX-2011P in Participants With Alzheimer's Disease — Associated Retina Consultants, PhoenixDeep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD) — UCLA TMS Clinical and Research Service, Los AngelesRepurposing Siponimod for Alzheimer's Disease — St. Joseph's Hospital and Medical Center, PhoenixBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonExercise to Improve Brain Health in Older African Americans — Rutgers, The State University of New Jersey - Newark campus, NewarkGlutathione, Brain Metabolism and Inflammation in Alzheimer's Disease — Baylor College of Medicine, HoustonUAB Alzheimer's Disease Center Core Cohort - Imaging Substudy — University of Alabama at Birmingham Medical Center, BirminghamAlzheimer's Tau Platform: Master Protocol — University of California, San Francisco, San FranciscoSleep Trial to Prevent Alzheimer's Disease — Washington University School of Medicine, St LouisAssessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease — Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, BostonHuman Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. — University of Miami Department of Neurology, MiamiDORA and LP in Alzheimer's Disease Biomarkers — Washington University in St. Louis, School of Medicine, St LouisPET Imaging Evaluation of [11C]SY08 — MGH, CharlestownOpen-Label Extension Protocol to SNK01-AD01 Study — Behavioral Research Specialists, LLC, GlendaleAssess Fibrin in Brains With AD/ADRD — Massachusetts General Hospital, BostonImpact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) — University of Texas Southwestern Medical Center, DallasNicotinic Acid for the Treatment of Alzheimer's Disease — IU Health Neuroscience Center, IndianapolisSleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND) — University of Virginia, CharlottesvilleUltralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol — Nuclear Imaging Institute, Englewood18F-mFBG Cardiac Uptake With Lewy Body Dementia — Houston Methodist Neurological Institute, HoustonBumetanide in Patients With Alzheimer's Disease — Stanford University, StanfordLow-Dose Radiotherapy for Alzheimer's Disease — Renaissance Institute of Precision Oncology & Radiosurgery, Winter ParkBrain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices) — MIT, CambridgeEffects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease — Eastern Virginia Medical School, NorfolkMindful Walking Neural Correlates of Executive Function in SC Older Adults at Risk of Dementias — University of South Carolina, ColumbiaRifaximin SSD in Dementia Trial — Richmond VA Medical Center, RichmondInterleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease — Houston Methodist Research Institute, HoustonClinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults — Johns Hopkins University School of Medicine, BaltimoreVortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia — The Johns Hopkins Hospital, BaltimoreALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults — Rutgers - Institute for Health, New BrunswickSV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy — Yale School of Medicne, Neuro ID Research Program, New HavenPET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases — Brigham MS Center, 60 Fenwood Road, BostonPhase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments — Domino's Farms, Ann ArborEducational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia — University of Texas at Austin, AustinFirst-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia — China Basin, UCSF, San FranciscoPhase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease — University of Colorado Anschutz Medical Campus, Aurora